Increased PLA(2) activity in individuals at ultra-high risk for psychosis

Autor(es)

Talib, Leda L. ^{[1, 2]} ; Costa, Alana C. ^{[1, 2]} ; Joaquim, Helena P. G. ^{[1, 2]} ; Pereira, Cicero A. C. ^{[1, 2]} ; van de Bilt, Martinus T. ^{[1, 2]} ; Loch, Alexandre A. ^{[1, 2]} ; Gattaz, Wagner F. ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Nacl Biomarcadores Neuropsiquiatria INBION, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Dept & Inst Psychiat, Lab Neurosci LIM 27, Sch Med, Rua Dr Ovidio Pires de Campos 785, 1st Floor, BR-05403010 Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE; v. 271, n. 8, p. 1593-1599, DEC 2021.
• Citações Web of Science: 0

Resumo

Phospholipase A(2) is the main enzyme in the metabolism of membrane phospholipids. It comprises a family of enzymes divided into iPLA(2), cPLA(2) and sPLA(2). Studies have reported increased PLA(2) activity in psychotic patients, which suggests an accelerated breakdown of membrane phospholipids. In the present study we investigated whether increased PLA(2) activity is also present in individuals at ultra-high risk (UHR) for psychosis. One-hundred fifty adults were included in this study (85 UHR and 65 controls). UHR was assessed using the ``structured interview for prodromal syndromes{''}. PLA(2) activity was determined in platelets by a radio-enzymatic assay. We found in UHR individuals increased activities of iPLA(2) (p < 0.001) and cPLA(2) (p = 0.012) as compared to controls. No correlations were found between socio-demographic and clinical parameters and PLA(2) activity. Our findings suggest that increased PLA(2) activities may be useful as a biological risk-marker for psychotic disorders. (AU)

• Processo FAPESP: 17/26291-2 - Marcadores periféricos de metabolismo de membrana: caracterização de indivíduos com alto risco para psicose
• Beneficiário: Alana Caroline Costa
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 14/50873-3 - INCT 2014: Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN)
• Beneficiário: Wagner Farid Gattaz
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 18/11414-4 - Alterações na via inflamatória da Cox: risco para o desenvolvimento de esquizofrenia
• Beneficiário: Cícero Augusto Costa Pereira
• Modalidade de apoio: Bolsas no Brasil - Mestrado